Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.

Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.

Item
http://www.wikidata.org/entity/Q36518457
Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical PathologyIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesTransition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade.In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii.New developments and controversies in iron metabolism and iron chelation therapy.Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Novel near-infrared fluorescent integrin-targeted DFO analogue.The Assessment of Skin Color and Iron Levels in Pediatric Patients with β-Thalassemia Major Using a Visual Skin Color Chart.Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy.Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.The effect of the oral iron chelator deferiprone on the liver damage induced by tamoxifen in female rats.Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
P2860

Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.

Item
http://www.wikidata.org/entity/Q36518457
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Iron mobilization from transfe ...... , cancer and other conditions.
@ast
Iron mobilization from transfe ...... , cancer and other conditions.
@en
type
label
Iron mobilization from transfe ...... , cancer and other conditions.
@ast
Iron mobilization from transfe ...... , cancer and other conditions.
@en
prefLabel
Iron mobilization from transfe ...... , cancer and other conditions.
@ast
Iron mobilization from transfe ...... , cancer and other conditions.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Iron mobilization from transfe ...... , cancer and other conditions.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P698